Liposomal constructs for antitumoral vaccination by the nasal route.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Biochimie

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biochi.2016.07.003PMID 27423321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination.

  2015cited by this paper
• Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity

  2014cited by this paper
• Liposomes as vaccine delivery systems: a review of the recent advances

  2014cited by this paper
• Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.

  2014cited by this paper
• Peptide Vaccine: Progress and Challenges

  2014cited by this paper
• Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.

  2013cited by this paper
• Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

  2013cited by this paper
• Mucosal vaccine design and delivery.

  2012cited by this paper
• Recent progress in mucosal vaccine development: potential and limitations

  2012cited by this paper
• New insights in mucosal vaccine development.

  2012cited by this paper
• Targeting tumor antigens to dendritic cells using particulate carriers.

  2012cited by this paper
• Effect of Chemical Enhancers in Transdermal Permeation of Alfuzosin Hydrochloride

  2012cited by this paper
• Mucosal vaccination: lung versus nose.

  2012cited by this paper
• Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

  2012cited by this paper
• Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.

  2012cited by this paper
• Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.

  2011cited by this paper
• Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways.

  2011cited by this paper
• Liposomes as delivery systems for nasal vaccination: strategies and outcomes

  2010cited by this paper
• CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.

  2010cited by this paper
• Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice.

  2010cited by this paper
• Bronchus-associated lymphoid tissue: an entry site for antigens for successful mucosal vaccinations?

  2010cited by this paper
• Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice.

  2010cited by this paper
• Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4+ and CD8+ T cells in the genital and intestinal tracts.

  2010cited by this paper
• Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine.

  2010cited by this paper
• Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.

  2010cited by this paper
• Design of a Liposomal Candidate Vaccine Against Pseudomonas aeruginosa and its Evaluation in Triggering Systemic and Lung Mucosal Immunity

  2009cited by this paper
• Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

  2009cited by this paper
• Highly Efficient Antiviral CD8+ T-Cell Induction by Peptides Coupled to the Surfaces of Liposomes

  2009cited by this paper
• Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice.

  2009cited by this paper
• Recent advances in liposomal dry powder formulations: preparation and evaluation

  2009cited by this paper
• A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice.

  2009cited by this paper
• Nanoparticles target distinct dendritic cell populations according to their size

  2008cited by this paper
• Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes

  2008cited by this paper
• Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.

  2006cited by this paper
• Liposomal vaccines--targeting the delivery of antigen.

  2006cited by this paper
• Vesicles as a tool for transdermal and dermal delivery.

  2005cited by this paper
• Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems.

  2005cited by this paper
• Tetanus toxoid‐loaded transfersomes for topical immunization

  2005cited by this paper
• Strong Mucosal and Systemic Immunities Induced by Nasal Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome–Protamine–DNA Particles

  2005cited by this paper
• Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study.

  2005cited by this paper
• Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines

  2004cited by this paper
• Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.

  2004cited by this paper
• Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia.

  2002cited by this paper
• Intravaginal and Intranasal Immunizations Are Equally Effective in Inducing Vaginal Antibodies and Conferring Protection against Vaginal Candidiasis

  2002cited by this paper
• Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention.

  2002cited by this paper
• Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.

  2002cited by this paper
• Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs.

  2000cited by this paper
• Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.

  1998cited by this paper

• Liposomal sprays for nasal vaccination: a comparative study of cationic and anionic formulations involving stability upon nebulization, sprayability, and in vitro immune activation

  2025cites this paper
• State-of-the-Art Review on Liposomes as Versatile Cancer Vaccine Delivery Systems

  2025cites this paper
• Liposome-based vaccines for minimally or noninvasive administration: an update on current advancements

  2023cites this paper
• Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery

  2023cites this paper
• Anti-inflammatory effects of free and liposome-encapsulated natural Algerian thermal water in RAW 264.7 macrophages.

  2022cites this paper
• Liposome-Based Nanovaccines

  2019cites this paper
• Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform.

  2019cites this paper
• Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery

  2019cites this paper
• Nanovaccines: An Innovative Technology to Fight Human and Animal Diseases

  2019cites this paper
• Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity

  2018cites this paper
• Enhancing tumor specific immune responses by transcutaneous vaccination

  2017cites this paper
• Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines

  2017cites this paper